175 related articles for article (PubMed ID: 17911445)
1. Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma.
Schachter J; Katz U; Mahrer A; Barak D; David LZ; Nusbacher J; Shoenfeld Y
Ann N Y Acad Sci; 2007 Sep; 1110():305-14. PubMed ID: 17911445
[TBL] [Abstract][Full Text] [Related]
2. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
[TBL] [Abstract][Full Text] [Related]
3. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
[TBL] [Abstract][Full Text] [Related]
4. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins--interim results on drug safety of an ongoing study. IVIG study group.
Poehlau D
Mult Scler; 2000 Oct; 6 Suppl 2():S21-3. PubMed ID: 11188774
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
12. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients.
Kreuter A; Gambichler T; Breuckmann F; Bechara FG; Rotterdam S; Stücker M; Altmeyer P
J Am Acad Dermatol; 2004 Oct; 51(4):574-9. PubMed ID: 15389193
[TBL] [Abstract][Full Text] [Related]
13. [Personal experience with replacement therapy with intravenous gamma globulin].
Litzman J; Lokaj J; Stikarovská D; Mayer J; Thon V; Eibl MM
Vnitr Lek; 1995 Nov; 41(11):759-63. PubMed ID: 8553594
[TBL] [Abstract][Full Text] [Related]
14. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.
Daoud Y; Amin KG; Mohan K; Ahmed AR
Ann Pharmacother; 2005 Dec; 39(12):2003-8. PubMed ID: 16264064
[TBL] [Abstract][Full Text] [Related]
15. IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies.
Zinman L; Bril V
Ann N Y Acad Sci; 2008; 1132():264-70. PubMed ID: 18567877
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.
Eigentler TK; Radny P; Hauschild A; Gutzmer R; Linse R; Pföhler C; Wagner SN; Schadendorf D; Ellwanger U; Garbe C;
Melanoma Res; 2008 Oct; 18(5):353-8. PubMed ID: 18781134
[TBL] [Abstract][Full Text] [Related]
18. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
[TBL] [Abstract][Full Text] [Related]
19. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
Rigas M; Tandan R; Sterling RJ
J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
[TBL] [Abstract][Full Text] [Related]
20. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis.
Al-Mutairi N; Arun J; Osama NE; Amr Z; Mazen AS; Ibtesam el-A; Nazeha el-B
Int J Dermatol; 2004 Nov; 43(11):847-51. PubMed ID: 15533072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
